SWX:ROGPharmaceuticals
Roche Trial Win In Rare Kidney Disease And What It Means For Valuation
Roche Holding (SWX:ROG) reported that its Phase III MAJESTY study in primary membranous nephropathy met its primary endpoint with Gazyva/Gazyvaro.
The result positions Gazyva/Gazyvaro as a potential first approved treatment for this rare kidney condition.
The outcome may support future regulatory submissions and broaden the medicine's approved indications.
For you as an investor, this sits at the heart of what Roche does: prescription medicines targeting areas with significant unmet medical...